NTG - myDSC

Resources for Professionals

Resources for Professionals

LuMind IDSC Statement on FDA Approval of Leqembi

Last week the FDA announced a full approval of a new drug called Leqembi to…

Kim WarrenJuly 13, 2023

Resources for Professionals

Resources for Professionals

Over-Medication and Older Adults with Intellectual Disability: Risks for Brain Health

"Over-Medication and Older Adults with Intellectual Disability: Risks for Brain Health," cautions users and families…

Capetivate capetivateFebruary 28, 2023

Health and Research – Other

Health and Research - COVID-19

Advisory on Long-COVID and Impact on Cognitive Function in Adults with Intellectual Disability

The purpose of this advisory is to provide background information on newly recognized cognitive impairments,…

Capetivate capetivateNovember 8, 2022

Alzheimers Dementia

Health and Research – Alzheimer's/Dementia

LuMind IDSC signs on to NTG statement re: Aduhelm

“It is unknown to what degree aducanumab (Aduhelm) may help people with Down syndrome, as…

Rigsby RigsbyOctober 27, 2021

Alzheimers Dementia

Health and Research – Alzheimer's/Dementia

LuMind IDSC and Other National Groups Urge CMS to Include DS Community in Alzheimer’s Drugs Coverage

LuMind IDSC has joined the National Down Syndrome Society (NDSS) and The National Task Group…

Rigsby RigsbyOctober 27, 2021

© 2024 myDSC.